Genprex Inc (GNPX)

$3.95 -0.52 (-11.73%)
Market Cap 2.26M
Revenue (ttm) 0.00
Net Income (ttm) -16.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,274,100
Avg Vol 198,086
Day's Range N/A - N/A
Shares Out 505,000.00
Stochastic %K 9%
Beta -0.88
Analysts Strong Buy
Price Target $164.84

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 774 4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
Kingjamesvii
Kingjamesvii Aug. 19 at 11:31 AM
$GNPX took a review of the upper management and oh boy... now I know why this is trash.
0 · Reply
Caracasloco
Caracasloco Aug. 19 at 10:50 AM
$GNPX mtfc i hope u can explode alive
0 · Reply
Caracasloco
Caracasloco Aug. 19 at 10:49 AM
$GNPX are u crazy??????
0 · Reply
Kingjamesvii
Kingjamesvii Aug. 19 at 10:40 AM
$GNPX yep mid 3s...just saying
0 · Reply
biotrade123
biotrade123 Aug. 19 at 3:18 AM
$GNPX Looks like retail who bought in expecting a pump to increase the float have not been able to realize any gains as the game is being played during AH/PM it appears??
0 · Reply
R0MER0
R0MER0 Aug. 19 at 2:01 AM
$GNPX add 1500 shares 3.89
0 · Reply
Hassan77
Hassan77 Aug. 19 at 1:30 AM
$GNPX moved on and sold this at $4.30 cant believe we didnt even get time to react to the pump on news this morning. I made $70K off this stock back in 2021 I may never touch it again after today GL all
0 · Reply
Jpeel1972
Jpeel1972 Aug. 18 at 10:29 PM
$GNPX it looks like the company has about 15 million left. To put that in perspective it would take 100 million to get requorsa to fda submission and another 200 million for commercial launch without a partner. Thats why every pop gets sold off so Cy quickly. They need someone other than retail to buy
1 · Reply
Kingjamesvii
Kingjamesvii Aug. 18 at 9:44 PM
$GNPX god this stock is awful. 😂
1 · Reply
RTPRwire
RTPRwire Aug. 18 at 9:31 PM
Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $CAST ran as much as +197% — product launch $GNPX ran as much as +62% — partnership $BIAF ran as much as +57% — partnership $AMLX ran as much as +39% — clinical trial results $SAGT ran as much as +38% — product launch Get real-time catalyst alerts using RTPR.
1 · Reply
Latest News on GNPX
Genprex selects manufacturing organization for diabetes gene therapy

2026-08-18T11:10:18.000Z - 1 day ago

Genprex selects manufacturing organization for diabetes gene therapy

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Aug 18, 2026, 7:00 AM EDT - 1 day ago

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

Genprex announces collaboration with Roche Diagnostics

2026-08-03T11:11:17.000Z - 16 days ago

Genprex announces collaboration with Roche Diagnostics

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex trading halted, news pending

2026-07-15T23:50:11.000Z - 4 weeks ago

Genprex trading halted, news pending

Genprex says CIPO issues Notice of Allowance for patent

2026-06-22T13:09:12.000Z - 2 months ago

Genprex says CIPO issues Notice of Allowance for patent

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Jun 22, 2026, 9:00 AM EDT - 2 months ago

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex to Participate at BIO International Convention 2026

Jun 17, 2026, 9:00 AM EDT - 2 months ago

Genprex to Participate at BIO International Convention 2026

Genprex files $250M mixed securities shelf

2026-06-05T21:05:10.000Z - 2 months ago

Genprex files $250M mixed securities shelf

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 26, 2026, 8:00 AM EDT - 3 months ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

2026-05-14T16:54:55.000Z - 3 months ago

Genprex collaborators present positive preclinical data of GPX-002 in diabetes

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

May 14, 2026, 8:00 AM EDT - 3 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex receives patent grant from The Israel Patent Office

2026-04-30T17:03:52.000Z - 3 months ago

Genprex receives patent grant from The Israel Patent Office

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Genprex enters research agreement with UT MD Anderson

2026-04-21T11:09:56.000Z - 4 months ago

Genprex enters research agreement with UT MD Anderson

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

2026-04-20T11:26:41.000Z - 4 months ago

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex collaborators present on use of Reqorsa at AACR meeting

2026-03-18T11:11:22.000Z - 5 months ago

Genprex collaborators present on use of Reqorsa at AACR meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex to Participate at BIO Europe Spring 2026

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Genprex to Participate at BIO Europe Spring 2026

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

2026-02-23T13:12:47.000Z - 6 months ago

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 23, 2026, 8:00 AM EST - 6 months ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

2026-02-10T13:05:58.000Z - 6 months ago

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Feb 10, 2026, 8:00 AM EST - 6 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 7, 2026, 7:00 AM EST - 8 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Genprex reports ‘positive’ preclinical data from study of GPX-002

2026-01-06T12:05:20.000Z - 8 months ago

Genprex reports ‘positive’ preclinical data from study of GPX-002

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Jan 6, 2026, 7:00 AM EST - 8 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

2025-11-24T12:10:18.000Z - 9 months ago

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 24, 2025, 7:00 AM EST - 9 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Genprex files to sell 1.28M shares of common stock for holders

2025-11-21T22:00:33.000Z - 9 months ago

Genprex files to sell 1.28M shares of common stock for holders

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

2025-11-19T12:10:46.000Z - 9 months ago

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

AZN

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 19, 2025, 7:00 AM EST - 9 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

2025-11-18T12:21:46.000Z - 9 months ago

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 18, 2025, 7:00 AM EST - 9 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex on path to receive European patent for Reqorsa in cancer

2025-11-04T12:50:41.000Z - 10 months ago

Genprex on path to receive European patent for Reqorsa in cancer

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Nov 4, 2025, 7:00 AM EST - 10 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex trading resumes

2025-10-28T15:30:20.000Z - 10 months ago

Genprex trading resumes

Genprex trading halted, volatility trading pause

2025-10-28T15:25:18.000Z - 10 months ago

Genprex trading halted, volatility trading pause

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 11:19 AM EDT - 10 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 28, 2025, 7:00 AM EDT - 10 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 8:12 AM EDT - 10 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 7:00 AM EDT - 10 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 18, 2025, 9:29 AM EDT - 1 year ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 1 year ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 1 year ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Kingjamesvii
Kingjamesvii Aug. 19 at 11:31 AM
$GNPX took a review of the upper management and oh boy... now I know why this is trash.
0 · Reply
Caracasloco
Caracasloco Aug. 19 at 10:50 AM
$GNPX mtfc i hope u can explode alive
0 · Reply
Caracasloco
Caracasloco Aug. 19 at 10:49 AM
$GNPX are u crazy??????
0 · Reply
Kingjamesvii
Kingjamesvii Aug. 19 at 10:40 AM
$GNPX yep mid 3s...just saying
0 · Reply
biotrade123
biotrade123 Aug. 19 at 3:18 AM
$GNPX Looks like retail who bought in expecting a pump to increase the float have not been able to realize any gains as the game is being played during AH/PM it appears??
0 · Reply
R0MER0
R0MER0 Aug. 19 at 2:01 AM
$GNPX add 1500 shares 3.89
0 · Reply
Hassan77
Hassan77 Aug. 19 at 1:30 AM
$GNPX moved on and sold this at $4.30 cant believe we didnt even get time to react to the pump on news this morning. I made $70K off this stock back in 2021 I may never touch it again after today GL all
0 · Reply
Jpeel1972
Jpeel1972 Aug. 18 at 10:29 PM
$GNPX it looks like the company has about 15 million left. To put that in perspective it would take 100 million to get requorsa to fda submission and another 200 million for commercial launch without a partner. Thats why every pop gets sold off so Cy quickly. They need someone other than retail to buy
1 · Reply
Kingjamesvii
Kingjamesvii Aug. 18 at 9:44 PM
$GNPX god this stock is awful. 😂
1 · Reply
RTPRwire
RTPRwire Aug. 18 at 9:31 PM
Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $CAST ran as much as +197% — product launch $GNPX ran as much as +62% — partnership $BIAF ran as much as +57% — partnership $AMLX ran as much as +39% — clinical trial results $SAGT ran as much as +38% — product launch Get real-time catalyst alerts using RTPR.
1 · Reply
Al_Paca
Al_Paca Aug. 18 at 9:02 PM
$GNPX over 4.05 and we’re off
1 · Reply
magababy2026
magababy2026 Aug. 18 at 8:40 PM
$GNPX added more now at 14k shares
1 · Reply
MajorGainz7
MajorGainz7 Aug. 18 at 7:55 PM
$GNPX ah mover?
1 · Reply
Al_Paca
Al_Paca Aug. 18 at 7:40 PM
$GNPX give us 6 AH
0 · Reply
Al_Paca
Al_Paca Aug. 18 at 7:37 PM
$GNPX interesting action here before close
0 · Reply
Jpeel1972
Jpeel1972 Aug. 18 at 7:34 PM
$GNPX once the price hits three dollars the market will automatically price in another reverse split, which will be just one more blow. They’ve dropped 50% in the last 33 days
0 · Reply
OverTheCounter
OverTheCounter Aug. 18 at 7:34 PM
$GNPX I might buy 100 shares when this hits 1$. To try my luck.
0 · Reply
MajorGainz7
MajorGainz7 Aug. 18 at 7:30 PM
$GNPX every other low float ran double digits
0 · Reply
bullseye86
bullseye86 Aug. 18 at 7:29 PM
$GNPX thx for another quick snatch under $4
0 · Reply
POSGNPX
POSGNPX Aug. 18 at 7:26 PM
$GNPX why keep falling for these AI generated bear traps. If there’s no news, there’s no news so there’s no reason for this to rise. They made $.78 to share last time now $.48 to share this time. 
0 · Reply
MajorGainz7
MajorGainz7 Aug. 18 at 7:22 PM
$GNPX grabbing some why isnt this running
2 · Reply
Vinniesb
Vinniesb Aug. 18 at 6:58 PM
$GNPX 2000 shares below $4.00 Hell Yea!
0 · Reply